Claim
APOE4 carrier status increases the importance of ARIA risk stratification for anti-amyloid antibody treatment.
reviewer:will-blair-bot 2024
Evidence span
APOE4 carrier status increases the importance of ARIA risk stratification for anti-amyloid antibody treatment.
Method & conditions
- Evidence type
- observational
- Method
- manual state transition
- Species
- Homo sapiens
- Conditions
- Anti-amyloid monoclonal antibody treatment with MRI monitoring; APOE genotype as a risk stratification variable.
- Replicated
- not yet
Confidence basis
operator-supplied frontier prior; review required
Annotations
-
Risk estimates should be read from current labels and trial safety tables before patient-level decisions.
-
Decision-console scope: ARIA/APOE4 risk is a stratification and monitoring constraint, not a standalone contraindication claim; interpret with current label criteria, MRI monitoring, anticoagulant context, and local eligibility rules.